Bedaquiline: a review of human pharmacokinetics and drug-drug interactions

Bedaquiline has recently been approved for the treatment of pulmonary multidrug-resistant tuberculosis (TB) as part of combination therapy in adults. It is metabolized primarily by the cytochrome P450 isoenzyme 3A4 (CYP3A4) to a less-active N-monodesmethyl metabolite. Phase I and Phase II studies in...

Celý popis

Podrobná bibliografie

Vydáno v:	Journal of antimicrobial chemotherapy Ročník 69; číslo 9; s. 2310
Hlavní autoři:	van Heeswijk, R P G, Dannemann, B, Hoetelmans, R M W
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 01.09.2014
Témata:	Antifungal Agents - pharmacology Antitubercular Agents - pharmacokinetics Antitubercular Agents - pharmacology Antiviral Agents - pharmacology Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Diarylquinolines - pharmacokinetics Diarylquinolines - pharmacology Drug Interactions Humans Tuberculosis, Multidrug-Resistant - drug therapy CYP3A clinical trials HIV tuberculosis
ISSN:	1460-2091, 1460-2091
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!